Compare BBN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBN | PHVS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 2.4B |
| IPO Year | 2010 | 2020 |
| Metric | BBN | PHVS |
|---|---|---|
| Price | $14.90 | $36.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.82 |
| AVG Volume (30 Days) | 153.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.85 | $20.65 |
| 52 Week High | $17.45 | $43.25 |
| Indicator | BBN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 25.32 | 50.83 |
| Support Level | N/A | $32.77 |
| Resistance Level | $16.02 | $36.80 |
| Average True Range (ATR) | 0.15 | 2.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 6.46 | 29.95 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.